Most life sciences procurement teams measure velocity at the wrong point. They time how fast they can pick a supplier and miss the part that delays the science: everything between the decision and the started study. R&D procurement velocity is the speed from "we chose this provider" to "the work has begun," and in regulated research that distance is where weeks disappear. Closing it is the difference between a procurement function that supports the science and the intelligent infrastructure that accelerates it.
The decision was never the bottleneck. It just needs to be executed properly.
Because every new engagement restarts a process that should carry forward. A new study often means a new contract negotiation, a fresh qualification cycle, a confidential disclosure agreement, and a new payment setup, even for a provider you have used before. Deloitte's research on R&D points to fragmented data and disconnected systems as a primary barrier to moving faster, and the same fragmentation surrounds procurement. Most of the work is repeated work the organization already did once.
The benefit of seeing onboarding as the velocity problem is that it is fixable. You cannot speed up science by rushing it. You can remove the procedural restarts that sit in front of it, which is exactly what purpose-built infrastructure is for.
Q: What is R&D procurement velocity in life sciences?
A: R&D procurement velocity is the speed at which a life sciences team moves from selecting an external provider to starting the contracted work. It measures the full path, including contracting, GxP qualification, confidential disclosure agreements, and payment setup, not just the sourcing decision. In regulated research, most of the delay sits in that execution path rather than in the choice itself.
A typical outsourced R&D engagement carries more than 50 hours of onboarding work across contract negotiation, compliance review, and payment configuration, before any data is generated. Multiply that by the number of providers a single program touches and the lost time is structural, not occasional. The cost is not only time. It is the scientist who is waiting to start while the paperwork clears.
This is also where the GxP and protocol-level requirements of regulated research separate life sciences from general business procurement. A provider is not usable until it is qualified for the specific work, and that qualification has to hold up to audit. Generic tools were not built to carry that forward.
There is real momentum behind smarter sourcing. In a 2025 McKinsey survey of more than 300 procurement leaders, 40% reported piloting generative AI, and the function could become 25 to 40% more efficient. That improves the decision. It does nothing for the execution behind it. A faster recommendation feeding a manual onboarding process is a better-informed delay, not a faster study.
Velocity comes from treating the decision and the execution as one connected path. The choice narrows the field. The infrastructure turns the chosen provider into a contracted, compliant, paid relationship without a scramble.
Q: How can pharma companies reduce supplier onboarding time for R&D services?
A: The fastest reductions come from removing repeated work: one pre-negotiated master agreement instead of per-supplier contracts, pre-qualified partners instead of fresh qualification each time, and a single payment relationship instead of new setup per vendor. Science Exchange consolidates these into one path, supporting roughly 6.5x faster project initiation compared with legacy onboarding processes.
The teams moving fastest are not the ones with the most aggressive sourcing timelines. They are the ones who built a path where qualification, contracting, and payment are handled once and reused. One pre-approved contract structure. One qualification standard. One payment entity standing between the team and thousands of pre-qualified partners. When that is in place, choosing a provider and starting the work stop being two separate projects.
That is the role Science Exchange plays. More than a marketplace that hands you a list, and more than an AI product, but as intelligent infrastructure for science: the layer that makes a sourcing decision executable.
Teams report 6.5x faster project initiation, which returns roughly five weeks per scientist per year to actual research, alongside reported cost savings of 21% on life science purchasing through optimized sourcing. The compliance is handled at the protocol level, and the platform is SOC 2 Type II certified, so velocity doesn't come at the cost of audit-readiness.
Q: Why are faster sourcing decisions alone not enough to speed up R&D?
A: A faster recommendation feeding a manual onboarding process is a better-informed delay, not a faster study. Velocity comes from treating the decision and the execution as one connected path, so the chosen provider becomes contracted, compliant, and paid without restarting qualification and contracting each time.
Pick one number and track it: the median days from supplier selection to study start. Then look at where those days go. If most of them sit in contracting, qualification, and payment setup that you have completed before for other studies, you are paying repeatedly for work that should carry forward. That gap is your velocity opportunity, and it is usually larger than the sourcing decision you have been trying to optimize.
If shortening that path is on your plate this year, it is worth seeing how the infrastructure handles it end to end.
See how Science Exchange turns a supplier decision into started science.